Banque Cantonale Vaudoise Sells 1,548 Shares of PetIQ, Inc. (NASDAQ:PETQ)

Banque Cantonale Vaudoise trimmed its stake in shares of PetIQ, Inc. (NASDAQ:PETQ) by 37.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,546 shares of the company’s stock after selling 1,548 shares during the quarter. Banque Cantonale Vaudoise’s holdings in PetIQ were worth $56,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CWM LLC boosted its position in PetIQ by 86.2% during the second quarter. CWM LLC now owns 1,251 shares of the company’s stock worth $28,000 after purchasing an additional 579 shares during the period. FinTrust Capital Advisors LLC boosted its position in shares of PetIQ by 50.2% in the first quarter. FinTrust Capital Advisors LLC now owns 2,618 shares of the company’s stock valued at $48,000 after acquiring an additional 875 shares during the period. Natixis Advisors L.P. boosted its position in shares of PetIQ by 10.2% in the fourth quarter. Natixis Advisors L.P. now owns 12,038 shares of the company’s stock valued at $237,000 after acquiring an additional 1,113 shares during the period. First Horizon Advisors Inc. bought a new stake in shares of PetIQ in the second quarter valued at about $36,000. Finally, ICA Group Wealth Management LLC bought a new stake in shares of PetIQ in the fourth quarter valued at about $35,000. 94.99% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Scott Huff sold 12,117 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $22.19, for a total value of $268,876.23. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 9.62% of the stock is currently owned by corporate insiders.

PetIQ Trading Down 0.1 %

PETQ opened at $30.53 on Wednesday. PetIQ, Inc. has a twelve month low of $15.09 and a twelve month high of $30.68. The company has a 50-day simple moving average of $25.32 and a 200 day simple moving average of $20.92. The company has a quick ratio of 1.68, a current ratio of 2.58 and a debt-to-equity ratio of 1.68. The stock has a market capitalization of $912.54 million, a price-to-earnings ratio of 138.78 and a beta of 1.71.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.20. The business had revenue of $328.90 million during the quarter, compared to analysts’ expectations of $330.14 million. PetIQ had a net margin of 1.20% and a return on equity of 18.75%. PetIQ’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.37 earnings per share. Analysts predict that PetIQ, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PETQ has been the subject of a number of recent research reports. Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of PetIQ in a research report on Friday, May 10th. Truist Financial cut shares of PetIQ from a “buy” rating to a “hold” rating and boosted their target price for the company from $30.00 to $31.00 in a research report on Thursday, August 8th. Finally, William Blair cut shares of PetIQ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.25.

PetIQ Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.